The novel coronavirus disease-19 (COVID-19) is a global pandemic that emerged from Wuhan, China, and has spread all around the world, affecting 216 countries or territories with 21,732,472 people infected and 770,866 deaths globally (as per WHO COVID-19 updates of August 18, 2020). Continuous efforts are being made to repurpose the existing drugs and develop vaccines for combating this infection. Despite, to date, no certified antiviral treatment or vaccine exists. Although, few candidates have displayed their efficacy in in vitro studies and are being repurposed for COVID- 19 treatment. This article summarizes synthetic and semi-synthetic compounds displaying potent activity in clinical uses or studies on COVID-19 and also focuses on the mode of action of drugs being repositioned against COVID-19.

Download full-text PDF

Source
http://dx.doi.org/10.2174/1389557520666201204162103DOI Listing

Publication Analysis

Top Keywords

synthetic semi-synthetic
8
covid-19
5
semi-synthetic drugs
4
drugs promising
4
promising therapeutic
4
therapeutic option
4
option treatment
4
treatment covid-19
4
covid-19 novel
4
novel coronavirus
4

Similar Publications

New semisynthetic α-glucosidase inhibitor from a doubly-chemically engineered extract.

Nat Prod Bioprospect

January 2025

Consejo Nacional de Investigaciones Científicas y Técnicas, Suipacha 531, S2002LRK, Rosario, Argentina.

Chemically engineered extracts represent a promising source of new bioactive semi-synthetic molecules. Prepared through direct derivatization of natural extracts, they can include constituents enriched with elements and sub-structures that are less common in natural products compared to drugs. Fourteen such extracts were prepared through sequential reactions with hydrazine and a fluorinating reagent, and their α-glucosidase inhibition properties were compared.

View Article and Find Full Text PDF

Randomized controlled trials (RCTs) evaluating anti-cancer agents often lack generalizability to real-world oncology patients. Although restrictive eligibility criteria contribute to this issue, the role of selection bias related to prognostic risk remains unclear. In this study, we developed TrialTranslator, a framework designed to systematically evaluate the generalizability of RCTs for oncology therapies.

View Article and Find Full Text PDF

Novel α-mangostin derivatives as promising antiviral agents: Isolation, synthesis, and evaluation against chikungunya virus.

Eur J Med Chem

December 2024

Department of Natural Products and Medicinal Chemistry, CSIR-IICT Hyderabad, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India. Electronic address:

Investigations into fruit and vegetable processing residues (FVPRs) offer huge opportunities to discover novel therapeutics against many diseases. In this study, detailed investigation of Garcinia mangostana fruit peel extract led to the isolation and identification of ten known compounds (1-10). Further, a new series of α-mangostin derived sulphonyl piperzines, aryl alkynes and 1,2,3-triazole derivatives were synthesized using Huisgen 1,3-dipolar cyclo-addition reaction ("click" chemistry).

View Article and Find Full Text PDF

Severe liver injury induced by minocycline in hepatitis B patient: a Case Report.

Front Pharmacol

December 2024

Pharmacy Department Nanjing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, Jiangsu Province, China.

Physical liver injury is an acute and potentially serious adverse event that may result in acute liver failure or even death. Diagnosis is often challenging. Minocycline, a semi-synthetic second-generation tetracycline, has high fat solubility and good tissue permeability.

View Article and Find Full Text PDF

Improved doramectin production based on high-throughput screening and medium optimization in .

Prep Biochem Biotechnol

January 2025

College of Chemical Engineering, Shijiazhuang University, Shijiazhuang, Hebei Province, China.

Doramectin, a 16-membered macrocyclic lactone that is widely used in the treatment of mammalian parasitic diseases. Doramectin was produced by mutant using cyclohexanecarboxylic acid as a precursor. As a semi-synthetic insecticidal agent produced, the production of doramectin was low, which could not be satisfy the demands of industrial fermentation.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!